Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
26.125 USD 0.57 ( 2.25%)
Last update at 2026-11-09T15:47:00Z
VOLUME
329434
Market Cap
2902.38M

Momentum Score

…

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.38
Low
26.25
High
52 Week Price Range
12.42
Low
31.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Arcutis Biotherapeutics is a U.S. biopharmaceutical company focused on dermatology, commercializing a topical PDE4 inhibitor (roflumilast cream) launched for plaque psoriasis and a pipeline of dermatology candidates. Long-term growth drivers include label expansions, new indications and scaling commercial penetration in a large specialty dermatology market; investors may find the company attractive for its focused franchise and early commercial traction.
The principal investment risk is execution and revenue uncertainty from early-stage commercialization, competitive pressures, reimbursement challenges and potential clinical or regulatory setbacks for pipeline programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
25.55
Dividend Yield
-
Revenue TTM
376.07M
Revenue Per Share
2.96
Gross Profit TTM
339.38M
Debt / Equity
0.03
ROE
-9.30%
Net Debt
-36.64M
ROCE
-0.95%
Diluted EPS TTM
-0.13

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.97M -139.39M -259.03M -311.46M -206.36M
Net income -16.14M -140.04M -262.14M -321.29M -205.90M
Selling general administrative 274.55M 222.49M 173.49M 122.12M 60.97M
Selling and marketing expenses - 6.90M - - -
Gross profit 339.38M 177.41M 54.62M 2.93M -
Reconciled depreciation 4.67M 2.60M 1.48M 0.93M 0.45M
Ebit -2.89M -112.22M -229.31M -301.63M -206.98M
Ebitda 2.48M -109.62M -227.43M -295.81M -206.53M
Depreciation and amortization 5.37M 2.60M 1.88M 5.82M 0.45M
Non operating income net other - - - - 0.17M
Operating income -12.23M -128.40M -241.10M -301.63M -206.53M
Other operating expenses 388.30M 324.94M 300.71M 305.31M 206.53M
Interest expense 12.08M 27.17M 29.71M 15.65M 0.45M
Tax provision 1.17M 0.65M 3.11M - -
Interest income 8.90M 16.13M 12.52M - -
Net interest income -3.19M -27.17M -28.86M -15.65M -
Income tax expense 1.17M 0.65M 3.11M 9.83M -0.45M
Total revenue 376.07M 196.54M 59.61M 3.69M 0.00M
Total operating expenses 351.60M 305.81M 295.72M 304.56M 206.53M
Cost of revenue 36.70M 19.13M 4.99M 0.75M -
Total other income expense net -2.74M -10.99M -17.93M -9.83M 0.17M
Net income from continuing ops -16.14M -140.04M -267.88M -311.46M -206.36M
Net income applicable to common shares - - - -311.46M -206.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 432.97M 348.89M 341.37M 449.27M 408.15M
Intangible assets 14.81M 9.48M 6.44M 7.19M -
Other current assets 21.39M 20.27M 18.70M 10.61M 14.17M
Total liab 243.49M 191.35M 252.70M 239.69M 110.47M
Total stockholder equity 189.48M 157.54M 88.67M 209.58M 297.68M
Other current liab 116.31M 65.97M 33.94M 28.32M 25.54M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1138.08M -1121.94M -981.90M -719.76M -408.31M
Other liab - - - - 0.03M
Other assets - - - 0.08M 0.08M
Cash 42.91M 71.33M 89.32M 53.64M 96.45M
Total current liabilities 129.84M 81.01M 46.67M 37.81M 33.33M
Net debt -36.64M 39.25M 116.59M 148.90M -18.89M
Short term debt 1.00M 0.82M 0.73M 0.66M 0.43M
Short long term debt 1.00M - - - -
Short long term debt total 6.27M 110.58M 205.92M 202.54M 77.56M
Other stockholder equity 1327.60M 1279.48M 1070.56M 930.42M 706.23M
Property plant equipment - - - 4.60M 2.26M
Total current assets 411.23M 335.82M 330.43M 437.41M 402.77M
Net tangible assets - - - 202.39M 297.68M
Short term investments 178.07M 156.62M 183.46M 355.95M 290.61M
Net receivables 146.23M 73.07M 25.81M 8.46M 0.36M
Long term debt 107.96M 107.20M 201.80M 197.77M 72.35M
Inventory 22.63M 14.53M 13.13M 7.51M 1.18M
Accounts payable 12.53M 14.22M 11.99M 8.83M 7.35M
Accumulated other comprehensive income -0.04M -0.01M 0.00M -1.09M -0.26M
Common stock total equity - - - - 0.01M
Retained earnings total equity - - - - -408.31M
Non currrent assets other 1.42M 0.60M 0.60M 0.08M 0.08M
Non current assets total 21.74M 13.07M 10.93M 11.87M 5.38M
Capital lease obligations 5.27M 3.38M 4.12M 4.77M 5.21M
Long term debt total - - - - 72.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -19.57M 28.82M 284.62M -87.20M -74.96M
Change to liabilities - - - 1.56M 10.71M
Total cashflows from investing activities -30.25M 28.82M 180.23M -87.20M -75.95M
Net borrowings 0.00M -100.00M 0.00M 125.00M 72.35M
Total cash from financing activities 6.97M 66.20M 101.32M 301.80M 281.95M
Change to operating activities - - - 4.23M 3.38M
Net income -16.14M -140.04M -262.14M -311.46M -206.36M
Change in cash -28.74M -17.37M 34.45M -43.12M 31.37M
Begin period cash flow 71.95M 89.32M 54.88M 97.99M 66.62M
End period cash flow 43.22M 71.95M 89.32M 54.88M 97.99M
Total cash from operating activities -5.62M -112.16M -247.06M -257.71M -174.63M
Issuance of capital stock 0.00M 161.68M 98.90M 176.05M 207.49M
Depreciation 4.67M 2.60M 1.52M 0.93M 0.45M
Other cashflows from investing activities -10.00M -5.00M - - -
Change to inventory -7.33M -0.40M -5.62M -7.51M -7.51M
Change to account receivables -73.16M -47.26M -17.35M -8.46M -8.46M
Sale purchase of stock - - - 12.47M 0.84M
Other cashflows from financing activities 6.97M 4.52M 2.42M 113.28M 73.61M
Change to netincome - - - 62.98M 23.89M
Capital expenditures 0.69M 0.14M 0.43M 23.28M 0.99M
Cash flows other operating - - - - -6.78M
Cash and cash equivalents changes - - - - 31.37M
Change in working capital -34.83M -15.08M -23.50M -10.18M 3.62M
Stock based compensation 40.36M 41.73M 38.81M 32.68M 23.89M
Other non cash items 0.31M -1.37M -1.75M 30.30M 0.31M
Free cash flow -6.31M -112.30M -247.49M -281.00M -175.62M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ARQT
Arcutis Biotherapeutics Inc		 0.57
2.25%		 26.12 - 135.14 7.72 16.02 7.79 1645.13
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

3027 Townsgate Road, Westlake Village, CA, United States, 91361

805 418 5006

https://www.arcutis.com

354

Name Title Year Born
Mr. Todd Franklin Watanabe M.A. Pres, CEO & Director 1968
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director 1955
Mr. Scott L. Burrows CFO & Principal Accounting Officer 1977
Dr. David W. Osborne Ph.D. Chief Technical Officer 1961
Dr. Patrick E. Burnett M.D., Ph.D. Sr. VP & Chief Medical Officer 1972
Mr. Matthew Richard Moore Sr. VP & Chief Bus. Officer 1974
Ms. Patricia A. Turney Sr. VP of Operations 1967
Mr. Eric McIntyre Head of Investor Relations NA
Ms. Courtney Barton VP and Chief Compliance Officer & Privacy Officer 1983
Mr. Masaru Matsuda Esq., J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…